Low levels of visible light (frequently red or near-infrared) can have significant therapeutic effects on multiple classes of diseases, injuries and medical dis¬orders. In particular it is effective for wound healing and pain control as well as reduction of inflammation and swelling. The recent acceptance of the MeSH term Photobiomodulation (PBM) Therapy by National Library of Medicine will facilitate more concerted efforts in the field at standardizing and optimizing many aspects of this exciting field.

It is believed that the primary intracellular chromophore that absorbs low levels of red and near-infrared light is cytochrome c oxidase, which is located in mitochondria. This absorption of energy may lead to increase in ATP synthesis and release of reactive oxygen species from the electron transport chain that can subsequently activate transcription factors and lead to cell proliferation and migration. A recently described extracellular mechanism involving activation of latent growth factor complex offers exciting new avenues to explore other PBM mechanisms.

Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, PBMT remains controversial. This likely is due to two main reasons; firstly the molecular mechanisms underlying the positive effects are incompletely understood. Secondly the complexity of rationally choosing among a large number of illumination parameters such as wavelength, fluence, power density, pulse structure and treatment timing has led to the pub¬lication of a number of negative studies as well as many positive ones.

This conference covers a field that is rapidly achieving a general level of acceptance in the medical and biomedical communities and will cover all of the important areas of PBMT research.

Contributed papers are solicited in the following areas (among others):
Well-controlled clinical trials in the following areas are strongly encouraged:
Topics we like are: ;
In progress – view active session
Conference BO110

Mechanisms of Photobiomodulation Therapy XVII

This conference has an open call for papers:
Abstract Due: 20 July 2022
Author Notification: 10 October 2022
Manuscript Due: 11 January 2023
Low levels of visible light (frequently red or near-infrared) can have significant therapeutic effects on multiple classes of diseases, injuries and medical dis¬orders. In particular it is effective for wound healing and pain control as well as reduction of inflammation and swelling. The recent acceptance of the MeSH term Photobiomodulation (PBM) Therapy by National Library of Medicine will facilitate more concerted efforts in the field at standardizing and optimizing many aspects of this exciting field.

It is believed that the primary intracellular chromophore that absorbs low levels of red and near-infrared light is cytochrome c oxidase, which is located in mitochondria. This absorption of energy may lead to increase in ATP synthesis and release of reactive oxygen species from the electron transport chain that can subsequently activate transcription factors and lead to cell proliferation and migration. A recently described extracellular mechanism involving activation of latent growth factor complex offers exciting new avenues to explore other PBM mechanisms.

Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, PBMT remains controversial. This likely is due to two main reasons; firstly the molecular mechanisms underlying the positive effects are incompletely understood. Secondly the complexity of rationally choosing among a large number of illumination parameters such as wavelength, fluence, power density, pulse structure and treatment timing has led to the pub¬lication of a number of negative studies as well as many positive ones.

This conference covers a field that is rapidly achieving a general level of acceptance in the medical and biomedical communities and will cover all of the important areas of PBMT research.

Contributed papers are solicited in the following areas (among others):
  • mechanistic studies and cellular chromophores
  • development of light sources for LLLT/PBMT (LED photomodulation; pulsed IR light therapy)
  • study of LLLT/PBMT dosimetry
  • in vitro research in mammalian cells
  • in vitro research in micro-organisms in culture
  • stimulation of wound healing and scar reduction in animal models
  • nerve regeneration and neural stimulation
  • prevention of ischemia-induced tissue death and regeneration.

Well-controlled clinical trials in the following areas are strongly encouraged:
  • stimulation of wound healing such as non-healing ulcers
  • treatments for stroke and degenerative brain disease
  • pain reduction in post-surgical and neuralgia patients
  • dental applications
  • dermatology applications
  • reduction of pain and inflammation in arthritis and other orthopedic conditions
  • macular degeneration prevention
  • reduction of edema

Topics we like are:
  • Interaction with chromaphores
  • Changes in redox state
  • Downstream molecular events
  • Changes in gene expression
  • Intracellular, membrane and extra cellular effects
  • Systemic/Episcopal and other indirect or distant effects
  • Physiological and immunological impacts
  • Clinical results
  • IIrradiation parameters
  • Dose dependent effects
  • Light sources (lasers, LEDs, polarised and broad spectrum lamps)
  • In vitro research in mammalian cells
  • Studies in animal models of disease
  • Safety contraindications, precustions, treatment reactions.
Conference Chair
THOR Photomedicine Ltd. (United Kingdom)
Conference Chair
Australasian Research Institute (Australia)
Program Committee
Univ. at Buffalo (United States)
Program Committee
Clark E. Tedford
LumiThera (United States)
Program Committee
Univ. of Wisconsin-Milwaukee (United States)
Program Committee
Harvard Medical School (United States), Wellman Ctr. for Photomedicine (United States)
Program Committee
Michael L. Denton
Air Force Research Lab. (United States)
Program Committee
Immunophotonics, Inc. (United States)